

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: IHC1/18 - Immunohistochemistry - Detection of HER-2/neu

Dead line: 01.05.2018

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

Test

Sample	Group		N	Result	N _{rel}
(601) A1 expression HER-2/neu					
Slide	(802) Dako HercepTest		4	Negative (1)	9,1 %
		>>>	6	Weak positivity	14 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	12	Weak positivity	27 %
	(804) Ventana PATHWAY anti-HER-2/neu		1	Negative (0)	2,3 %
			3	Negative (1)	6,8 %
		>>>	18	Weak positivity	41 %
Total per sample: n = 44			Success: 82 %	-----	
Total success: 82 %					
(602) A2 expression HER-2/neu					
Slide	(802) Dako HercepTest		2	Negative (1)	4,5 %
		>>>	8	Weak positivity	18 %
	(803) Dako c-erbB-2 Onkoprotein		4	Negative (1)	9,1 %
		>>>	8	Weak positivity	18 %
	(804) Ventana PATHWAY anti-HER-2/neu		2	Negative (0)	4,5 %
			10	Negative (1)	23 %
		>>>	10	Weak positivity	23 %
Total per sample: n = 44			Success: 59 %	-----	
Total success: 59 %					
(603) A3 expression HER-2/neu					
Slide	(802) Dako HercepTest	>>>	7	Negative (0)	16 %
		>	3	Negative (1)	6,8 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	6	Negative (0)	14 %
		>	6	Negative (1)	14 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	19	Negative (0)	43 %
		>	3	Negative (1)	6,8 %
Total per sample: n = 44			Success: 100 %	-----	
Total success: 100 %					
(606) B1 expression HER-2/neu					
Slide	(802) Dako HercepTest	>>>	10	Strong positivity	23 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	12	Strong positivity	27 %
	(804) Ventana PATHWAY anti-HER-2/neu	>	1	Weak positivity	2,3 %
		>>>	21	Strong positivity	48 %
Total per sample: n = 44			Success: 100 %	-----	
Total success: 100 %					
(607) B2 expression HER-2/neu					
Slide	(802) Dako HercepTest	>>>	10	Negative (0)	23 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	12	Negative (0)	27 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	22	Negative (0)	50 %
Total per sample: n = 44			Success: 100 %	-----	
Total success: 100 %					
(608) B3 expression HER-2/neu					
Slide	(802) Dako HercepTest		5	Negative (1)	11 %
		>>>	5	Weak positivity	11 %
	(803) Dako c-erbB-2 Onkoprotein		1	Negative (1)	2,3 %
		>>>	11	Weak positivity	25 %
	(804) Ventana PATHWAY anti-HER-2/neu		1	Negative (0)	2,3 %
			2	Negative (1)	4,5 %
		>>>	19	Weak positivity	43 %
Total per sample: n = 44			Success: 80 %	-----	
Total success: 80 %					
(611) C1 expression HER-2/neu					
Slide	(802) Dako HercepTest	>>>	9	Negative (0)	20 %
		>	1	Negative (1)	2,3 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	7	Negative (0)	16 %
		>	5	Negative (1)	11 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	19	Negative (0)	43 %
		>	3	Negative (1)	6,8 %
Total per sample: n = 44			Success: 100 %	-----	
Total success: 100 %					
(612) C2 expression HER-2/neu					
Slide	(802) Dako HercepTest		5	Negative (1)	11 %
		>>>	5	Weak positivity	11 %

Test					
Sample	Group		N	Result	N _{rel}
Slide	(803) Dako c-erbB-2 Onkoprotein	>>>	12	Weak positivity	27 %
	(804) Ventana PATHWAY anti-HER-2/neu		1	Negative (0)	2,3 %
			2	Negative (1)	4,5 %
		>>>	19	Weak positivity	43 %
	Total per sample: n = 44		Success: 82 %		
Total success: 82 %					
(613) C3 expression HER-2/neu					
Slide	(802) Dako HercepTest	>>>	10	Negative (0)	23 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	12	Negative (0)	27 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	22	Negative (0)	50 %
Total per sample: n = 44		Success: 100 %			
Total success: 100 %					
(616) D1 expression HER-2/neu					
Slide	(802) Dako HercepTest		3	Negative (1)	6,8 %
		>>>	7	Weak positivity	16 %
	(803) Dako c-erbB-2 Onkoprotein		2	Negative (1)	4,5 %
		>>>	10	Weak positivity	23 %
		>>>	2	Negative (0)	4,5 %
(804) Ventana PATHWAY anti-HER-2/neu		9	Negative (1)	20 %	
	>>>	11	Weak positivity	25 %	
Total per sample: n = 44		Success: 64 %			
Total success: 64 %					
(617) D2 expression HER-2/neu					
Slide	(802) Dako HercepTest	>>>	10	Strong positivity	23 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	12	Strong positivity	27 %
		>	1	Weak positivity	2,3 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	21	Strong positivity	48 %
Total per sample: n = 44		Success: 100 %			
Total success: 100 %					
(618) D3 expression HER-2/neu					
Slide	(802) Dako HercepTest		1	Negative (1)	2,3 %
		>>>	9	Weak positivity	20 %
	(803) Dako c-erbB-2 Onkoprotein		3	Negative (1)	6,8 %
		>>>	9	Weak positivity	20 %
		>>>	2	Negative (0)	4,5 %
(804) Ventana PATHWAY anti-HER-2/neu		8	Negative (1)	18 %	
	>>>	12	Weak positivity	27 %	
Total per sample: n = 44		Success: 68 %			
Total success: 68 %					
(621) E1 expression HER-2/neu					
Slide	(802) Dako HercepTest	>>>	10	Negative (0)	23 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	12	Negative (0)	27 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	22	Negative (0)	50 %
Total per sample: n = 44		Success: 100 %			
Total success: 100 %					
(622) E2 expression HER-2/neu					
Slide	(802) Dako HercepTest	>>>	7	Negative (0)	16 %
		>	3	Negative (1)	6,8 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	6	Negative (0)	14 %
		>	6	Negative (1)	14 %
		>>>	19	Negative (0)	43 %
(804) Ventana PATHWAY anti-HER-2/neu		3	Negative (1)	6,8 %	
	>	3	Negative (1)	6,8 %	
Total per sample: n = 44		Success: 100 %			
Total success: 100 %					
(623) E3 expression HER-2/neu					
Slide	(802) Dako HercepTest	>>>	10	Strong positivity	23 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	12	Strong positivity	27 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	22	Strong positivity	50 %
Total per sample: n = 44		Success: 100 %			
Total success: 100 %					
(651) A1 sample staining					
Slide	(0) not specified		3	0 points	6,8 %
		>	1	9 points	2,3 %
		>	1	10 points	2,3 %
		>	1	12 points	2,3 %
		>>>	1	13 points	2,3 %

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: IHC1/18 - Immunohistochemistry - Detection of HER-2/neu

Dead line: 01.05.2018

Test

Sample	Group	N	Result	N _{rel}
Slide	(0) not specified	>>> 37	15 points	84 %
Total per sample: n = 44		Success: 93 %		
Total success: 93 %				
(652) A2 sample staining				
Slide	(0) not specified	3	0 points	6,8 %
		>	5 9 points	11 %
		>>>	1 13 points	2,3 %
		>>>	35 15 points	80 %
Total per sample: n = 44		Success: 93 %		
Total success: 93 %				
(653) A3 sample staining				
Slide	(0) not specified	>	3 12 points	6,8 %
		>>>	1 13 points	2,3 %
		>>>	40 15 points	91 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				
(656) B1 sample staining				
Slide	(0) not specified	>>>	1 13 points	2,3 %
		>>>	43 15 points	98 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				
(657) B2 sample staining				
Slide	(0) not specified	>>>	44 15 points	100 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				
(658) B3 sample staining				
Slide	(0) not specified	2	0 points	4,5 %
		>	1 8 points	2,3 %
		>	4 9 points	9,1 %
		>>>	1 13 points	2,3 %
		>>>	36 15 points	82 %
Total per sample: n = 44		Success: 95 %		
Total success: 95 %				
(661) C1 sample staining				
Slide	(0) not specified	>	3 12 points	6,8 %
		>>>	1 13 points	2,3 %
		>>>	40 15 points	91 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				
(662) C2 sample staining				
Slide	(0) not specified	2	0 points	4,5 %
		1	6 points	2,3 %
		>	1 8 points	2,3 %
		>	1 9 points	2,3 %
		>>>	1 14 points	2,3 %
		>>>	38 15 points	86 %
Total per sample: n = 44		Success: 93 %		
Total success: 93 %				
(663) C3 sample staining				
Slide	(0) not specified	>>>	44 15 points	100 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				
(666) D1 sample staining				
Slide	(0) not specified	3	0 points	6,8 %
		>	3 9 points	6,8 %
		>>>	1 14 points	2,3 %
		>>>	37 15 points	84 %
Total per sample: n = 44		Success: 93 %		
Total success: 93 %				
(667) D2 sample staining				
Slide	(0) not specified	>>>	1 13 points	2,3 %
		>>>	43 15 points	98 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: IHC1/18 - Immunohistochemistry - Detection of HER-2/neu

Dead line: 01.05.2018

Test

Sample	Group	N	Result	N _{rel}
(668) D3 sample staining				
Slide	(0) not specified	2	0 points	4,5 %
		>	5 9 points	11 %
		>>>	1 13 points	2,3 %
		>>>	1 14 points	2,3 %
		>>>	35 15 points	80 %
Total per sample: n = 44		Success: 95 %		
Total success: 95 %				
(671) E1 sample staining				
Slide	(0) not specified	>>>	44 15 points	100 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				
(672) E2 sample staining				
Slide	(0) not specified	>	5 12 points	11 %
		>>>	1 14 points	2,3 %
		>>>	38 15 points	86 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				
(673) E3 sample staining				
Slide	(0) not specified	>>>	1 13 points	2,3 %
		>>>	43 15 points	98 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				
(681) IQC				
Slide	(0) not specified	1	0 points (unacceptable result)	2,3 %
		7	3 points (unacceptable result)	16 %
		>	13 6 points (acceptable result)	30 %
		>>>	23 9 points (excellent result)	52 %
Total per sample: n = 44		Success: 82 %		
Total success: 82 %				

st_kl

End of report

Printed: 15.05.2018